Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to -$1.6 million.

  • Angiodynamics' Cash from Investing Activities rose 1733.81% to -$1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$9.0 million, marking a year-over-year decrease of 13957.36%. This contributed to the annual value of -$10.2 million for FY2025, which is 10822.68% down from last year.
  • Per Angiodynamics' latest filing, its Cash from Investing Activities stood at -$1.6 million for Q4 2025, which was up 1733.81% from -$1.6 million recorded in Q3 2025.
  • Over the past 5 years, Angiodynamics' Cash from Investing Activities peaked at $98.4 million during Q3 2023, and registered a low of -$9.1 million during Q2 2021.
  • Over the past 5 years, Angiodynamics' median Cash from Investing Activities value was -$2.4 million (recorded in 2024), while the average stood at $3.5 million.
  • As far as peak fluctuations go, Angiodynamics' Cash from Investing Activities tumbled by 51825.56% in 2021, and later surged by 285285.23% in 2023.
  • Over the past 5 years, Angiodynamics' Cash from Investing Activities (Quarter) stood at -$3.8 million in 2021, then surged by 35.15% to -$2.5 million in 2022, then increased by 28.17% to -$1.8 million in 2023, then fell by 9.37% to -$2.0 million in 2024, then grew by 17.34% to -$1.6 million in 2025.
  • Its Cash from Investing Activities was -$1.6 million in Q4 2025, compared to -$1.6 million in Q3 2025 and -$2.6 million in Q2 2025.